Name and Address of Beneficial Owner
|
| |
Number of
Shares Beneficially Owned |
| |
Percentage
Beneficially Owned |
| ||||||
The Robert F. Shipley Family Trust
P.O. Box 894 Nogales, Arizona 85628 |
| | | | 2,773,363(1) | | | | | | 8.6% | | |
BlackRock, Inc.
55 East 52nd St. New York, NY 10055 |
| | | | 1,985,640 | | | | | | 6.2% | | |
Name of Beneficial Owner(1)
|
| |
Number
of Shares |
| |
Percentage
of Common Stock(1) |
| ||||||
Al W. Kraus
|
| | | | 188,121(2) | | | | | | * | | |
Phillip P. Chan, MD, PhD
|
| | | | 718,131(3) | | | | | | 2.2% | | |
Vincent J. Capponi, MS
|
| | | | 471,235(4) | | | | | | 1.4% | | |
Kathleen P. Bloch, CPA
|
| | | | 237,494(5) | | | | | | * | | |
Eric R. Mortensen, MD, PhD
|
| | | | 111,915(6) | | | | | | * | | |
Michael G. Bator
|
| | | | 50,700(7) | | | | | | * | | |
Edward R. Jones, MD, MBA
|
| | | | 75,700(8) | | | | | | * | | |
Alan D. Sobel, CPA
|
| | | | 46,200(9) | | | | | | * | | |
All current directors, director nominees and executive officers as a group (8 persons)
|
| | | | 1,899,496 | | | | | | 5.6% | | |
|
Name
|
| |
Age
|
| |
Director
Since |
| |
Principal Occupation, Other Business Experience
During Past Five Years and Other Directorships |
|
Phillip P. Chan, MD, PhD | | |
48
|
| |
2008
|
| | Dr. Chan became a director of CytoSorbents in 2008, and since January 2009 has served as our President and Chief Executive Officer. Prior to joining CytoSorbents, Dr. Chan led healthcare and life science investments for the NJTC Venture Fund from 2003 to 2008, most recently as a Partner. In 2006, Dr. Chan co-founded Andrew Technologies, a medical device company commercializing its U.S. Food and Drug Administration, or FDA, -approved HydraSolveTM lipoplasty system for plastic surgery. He is an Internal Medicine physician with a strong background in clinical medicine and research. Dr. Chan received his MD and PhD from the Yale University School of Medicine, completed his Internal Medicine residency at the Beth Israel Deaconess Medical Center at Harvard Medical School, and received his Board certification. He also holds a BS in cell and molecular biology from Cornell University. | |
Al W. Kraus(1)(2)(3)
|
| |
74
|
| |
2003
|
| | Mr. Kraus has been a director of CytoSorbents since 2003, and has been Chairman of our Board since 2009. From 2003 through 2008, Mr. Kraus also served as our President and Chief Executive Officer. Prior to joining CytoSorbents, from 2001 to 2003, Mr. Kraus served as President and Chief Executive Officer of NovoVascular Inc., an early stage company developing coated stent technology. From 1996 to 1998, Mr. Kraus served as President and Chief Executive Officer of Althin Healthcare and from 1998 to 2000, served as President and Chief Executive Officer of Althin Medical Inc., a manufacturer of products for the treatment of end stage renal disease. While Chief Executive Officer of Althin Healthcare, he provided strategic direction and management for operations throughout the Americas. From 1985 through 1989, Mr. Kraus served as Chief Executive Officer of Victor Technologies, formerly known as Micronics, a computer company, and from 1979 to 1985, he was U.S. Subsidiary Manager and Chief Operating Officer of Gambro Inc., a leading medical technology and healthcare company. Mr. Kraus was the Chief Operating Officer of Gambro when it went public in the United States in an offering led by Morgan Stanley. Mr. Kraus holds a BS in Business Administration from St. Joseph’s University. | |
Name
|
| |
Age
|
| |
Director
Since |
| |
Principal Occupation, Other Business Experience
During Past Five Years and Other Directorships |
|
Edward R. Jones, MD, MBA(1)(3)
|
| |
70
|
| |
2007
|
| | Dr. Jones has been a director of the Company since April 2007. Dr. Jones has been an attending physician at Albert Einstein Medical Center and Chestnut Hill Hospital as well as Clinical Professor of Medicine at Temple University Hospital since 1985. Dr. Jones has published or contributed to the publishing of 30 chapters, articles, and abstracts on the subject of treating kidney-related illnesses. He has been a member of the Renal Physicians Association, the Philadelphia County Medical Society for 17 years, and is a past board member of the National Kidney Foundation of the Delaware Valley. From March 2009 to March 2011, Dr. Jones is past-President of, and past Counselor at, the Renal Physicians Association. Dr. Jones is past Chairman of Kidney Care Partners, and he is past President of Delaware Valley Nephrology and Hypertension, Associates. He retired from that practice in June 30, 2018. Dr. Jones graduated from The Medical University of South Carolina and completed his Internal Medicine Residency at Temple University Hospital (TUH). He later served as Chief Medical Resident at Temple University Hospital. He was a fellow in the Renal and Electrolyte Section of the University of Pennsylvania after which he joined the faculty of Temple where he ran the renal physiology laboratory while teaching and providing patient care. Dr. Jones received his MBA in healthcare management from St Joseph’s University in Philadelphia. | |
Name
|
| |
Age
|
| |
Director
Since |
| |
Principal Occupation, Other Business Experience
During Past Five Years and Other Directorships |
|
Michael G. Bator(2) | | |
55
|
| |
2015
|
| | Mr. Bator has been a director of CytoSorbents since July 2015. Mr. Bator is a founder and partner of Quartz Advisory Group, LLC, a capital markets investment bank. Mr. Bator is the founder and partner of Certus Advisory, a consulting firm he founded in February 2015. From April 2015 to December 2016, Mr. Bator was the Chief Financial Officer of Trek Therapeutics, a development stage pharmaceutical company. From January 2001 until February 2015, Mr. Bator held several positions with Jennison Associates, a United States mutual and pension fund management company, where he was most recently Managing Director, Healthcare Research. Prior to that time, he worked in management consulting with Cambridge Pharma Consultancy, Lexington Strategy, and The Boston Consulting Group. Since March 2015, Mr. Bator has served on the board of directors of 3DBio Corporation, a private company focused on bioprinted cartilage implants used in reconstructive and orthopedic surgery. Since June 2017, Mr. Bator has served on the board of directors of Hippo Technologies, LLC., a technology company focused on helping consumers manage their prescriptions. Mr. Bator received his MBA in Finance from Wharton Business School at the University of Pennsylvania, and his BA from Princeton University. | |
Alan D. Sobel, CPA(1)(3)
|
| |
58
|
| |
2014
|
| | Mr. Sobel has been a director of CytoSorbents since 2014. Since 1996, Mr. Sobel has served as the Managing Member of Sobel & Co., LLC, a full-service accounting, auditing, taxation, and business consulting firm. He has provided corporate advisory and consulting services, including mergers and acquisitions, for clients in the real estate, manufacturing, pharmaceutical, and distribution businesses, among others. Mr. Sobel is a Certified Public Accountant, and has served in various leadership roles including Chairman of the Audit Committee of the New Jersey Society of Certified Public Accountants. Mr. Sobel received his BS in accounting from Bentley College and his MS in taxation from Fairleigh Dickinson University. | |
Name
|
| |
Fees
Earned or Paid in Cash ($) |
| |
Stock
Awards ($)(1) |
| |
Option
Awards ($)(2) |
| |
Total
($) |
| ||||||||||||
Michael G. Bator
|
| | | $ | 22,000 | | | | | | — | | | | | | 68,275(3) | | | | | $ | 90,275 | | |
Edward R. Jones, MD, MBA
|
| | | $ | 23,100 | | | | | | — | | | | | | 68,275(4) | | | | | $ | 91,375 | | |
Al W. Kraus
|
| | | $ | 48,400 | | | | | | — | | | | | | 136,432(5) | | | | | $ | 184,832 | | |
Alan D. Sobel, CPA
|
| | | $ | 31,900 | | | | | | — | | | | | | 68,275(6) | | | | | $ | 100,175 | | |
Name
|
| |
Age
|
| |
Position
|
|
Phillip P. Chan, MD, PhD | | |
48
|
| | President and Chief Executive Officer | |
Vincent J. Capponi, MS | | |
61
|
| | Chief Operating Officer | |
Kathleen P. Bloch, CPA, MBA | | |
64
|
| | Chief Financial Officer | |
Eric R. Mortensen, MD, PhD | | |
60
|
| | Chief Medical Officer | |
Named Executive Officer
|
| |
2018
Base Salary |
| |
2017
Base Salary |
| |
%
Increase from 2017 to 2018 |
| |||||||||
Phillip P. Chan, MD, PhD
|
| | | $ | 400,000 | | | | | $ | 378,000 | | | | | | 5.8% | | |
Vincent J. Capponi, MS
|
| | | $ | 332,000 | | | | | $ | 314,000 | | | | | | 5.7% | | |
Kathleen P. Bloch, CPA
|
| | | $ | 295,000 | | | | | $ | 275,000 | | | | | | 7.3% | | |
Eric R. Mortensen, MD, PhD
|
| | | $ | 339,000 | | | | | $ | 330,000 | | | | | | 2.7% | | |
Name and Principal Position
|
| |
Year
|
| |
Salary
($) |
| |
Bonus
($) |
| |
Stock
Awards(1) ($) |
| |
Option
Awards(2) ($) |
| |
All Other
Compensation |
| |
Total
($) |
| |||||||||||||||||||||
Phillip P. Chan, MD, PhD
President and Chief Executive Officer |
| | | | 2018 | | | | | | 400,000 | | | | | | 160,000 | | | | | | 337,550(3) | | | | | | 337,745 | | | | | | 12,000 | | | | | | 1,247,295 | | |
| | | 2017 | | | | | | 378,000 | | | | | | — | | | | | | 227,500(4) | | | | | | 210,097 | | | | | | 12,000 | | | | | | 827,597 | | | ||
| | | 2016 | | | | | | 350,000 | | | | | | — | | | | | | 121,940(5) | | | | | | 23,262 | | | | | | 12,000 | | | | | | 507,202 | | | ||
Vincent J. Capponi, MS
Chief Operating Officer |
| | | | 2018 | | | | | | 332,000 | | | | | | 132,800 | | | | | | 298,300(3) | | | | | | 316,520 | | | | | | — | | | | | | 1,079,620 | | |
| | | 2017 | | | | | | 314,000 | | | | | | — | | | | | | 201,253(4) | | | | | | 198,185 | | | | | | — | | | | | | 713,438 | | | ||
| | | 2016 | | | | | | 291,000 | | | | | | — | | | | | | 107,870(5) | | | | | | 21,932 | | | | | | — | | | | | | 420,802 | | | ||
Kathleen P. Bloch, MBA,
CPA Chief Financial Officer |
| | | | 2018 | | | | | | 295,000 | | | | | | 118,000 | | | | | | 272,395(3) | | | | | | 268,188 | | | | | | — | | | | | | 953,583 | | |
| | | 2017 | | | | | | 275,000 | | | | | | — | | | | | | 183,753(4) | | | | | | 167,861 | | | | | | — | | | | | | 626,614 | | | ||
| | | 2016 | | | | | | 255,000 | | | | | | — | | | | | | 98,490(5) | | | | | | 18,609 | | | | | | — | | | | | | 372,099 | | | ||
Eric R. Mortensen, MD, PhDChief Medical Officer
|
| | | | 2018 | | | | | | 339,000 | | | | | | 101,700 | | | | | | 109,900(3) | | | | | | 229,466 | | | | | | — | | | | | | 780,066 | | |
| | | 2017 | | | | | | 186,576 | | | | | | — | | | | | | — | | | | | | 116,700 | | | | | | — | | | | | | 303,276 | | |
Name
|
| |
Grant date
|
| |
Estimated
future payouts under equity incentive plan awards Target (#)(1) |
| |
Exercise or
base price of option awards ($/Sh) |
| |
Grant date fair
value of stock and option awards ($)(2)(3) |
| ||||||||||||
Phillip P. Chan, MD, PhD | | | | | | | | | | | | | | | | | | | | | | | | | |
RSUs(2) | | | | | 3/15/2018 | | | | | | 10,300 | | | | | | — | | | | | | — | | |
RSUs(3) | | | | | 2/28/2018 | | | | | | 43,000 | | | | | $ | 7.85 | | | | | $ | 337,550 | | |
Options(4) | | | | | 3/15/2018 | | | | | | 70,650 | | | | | $ | 7.90 | | | | | $ | 337,745 | | |
Vincent J. Capponi, MS | | | | | | | | | | | | | | | | | | | | | | | | | |
RSUs(2) | | | | | 3/15/2018 | | | | | | 10,100 | | | | | | — | | | | | | — | | |
RSUs(3) | | | | | 2/28/2018 | | | | | | 38,000 | | | | | $ | 7.85 | | | | | $ | 298,300 | | |
Options(4) | | | | | 3/15/2018 | | | | | | 66,210 | | | | | $ | 7.90 | | | | | $ | 316,520 | | |
Kathleen P. Bloch, CPA | | | | | | | | | | | | | | | | | | | | | | | | | |
RSUs(2) | | | | | 3/15/2018 | | | | | | 8,800 | | | | | | — | | | | | | — | | |
RSUs(3) | | | | | 2/28/2018 | | | | | | 34,700 | | | | | $ | 7.85 | | | | | $ | 272,395 | | |
Options(4) | | | | | 3/15/2018 | | | | | | 56,100 | | | | | $ | 7.90 | | | | | $ | 268,188 | | |
Eric R. Mortensen, MD, PhD | | | | | | | | | | | | | | | | | | | | | | | | | |
RSUs(2) | | | | | 3/15/2018 | | | | | | 20,000 | | | | | | — | | | | | | — | | |
RSUs(3) | | | | | 2/28/2018 | | | | | | 14,000 | | | | | $ | 7.85 | | | | | $ | 109,900 | | |
Options(4) | | | | | 3/15/2018 | | | | | | 48,000 | | | | | $ | 7.90 | | | | | $ | 229,466 | | |
| | |
Option Awards
|
| |
Stock Awards
|
| | | | ||||||||||||||||||||||||||||||||||||
Name
|
| |
Number of
Securities Underlying Unexercised Options (#) Exercisable |
| |
Equity
incentive plan awards: number of securities underlying unexercised unearned options (#) |
| |
Option
Exercise Price ($) |
| |
Option
Expiration Date |
| |
Equity
incentive plan awards: number of unearned shares, units or other rights that have not vested (#)(2) |
| |
Equity
incentive plan awards: market or payout value of unearned shares, units or other rights that have not vested ($)(3) |
| | | | ||||||||||||||||||||||||
Phillip P. Chan, MD, PhD
|
| | | | 20,000 | | | | | | | | | | | | 4.325 | | | | | | 1/4/2020 | | | | | | | | | | | | | | | | | | ||||||
| | | | | 89,100 | | | | | | | | | | | | 3.450 | | | | | | 5/5/2020 | | | | | | | | | | | | | | | | | | ||||||
| | | | | 30,500 | | | | | | | | | | | | 2.875 | | | | | | 4/4/2023 | | | | | | | | | | | | | | | | | | ||||||
| | | | | 66,500 | | | | | | | | | | | | 4.875 | | | | | | 3/28/2024 | | | | | | | | | | | | | | | | | | ||||||
| | | | | 7,000 | | | | | | | | | | | | 8.070 | | | | | | 4/8/2025 | | | | | | | | | | | | | | | | | | ||||||
| | | | | 77,600 | | | | | | | | | | | | 4.690 | | | | | | 6/7/2026 | | | | | | | | | | | | | | | | | | ||||||
| | | | | 95,200 | | | | | | | | | | | | 5.600 | | | | | | 2/24/2027 | | | | | | | | | | | | | | | | | | ||||||
| | | | | | | | | | | 70,650(1) | | | | | | 7.900 | | | | | | 3/15/2028 | | | | | | | | | | | | | | | | | | ||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 258,209 | | | | | | 2,086,329 | | | | | | ||||||
Vincent J. Capponi, MS
|
| | | | 20,000 | | | | | | | | | | | | 4.325 | | | | | | 1/4/2020 | | | | | | | | | | | | | | | | | | ||||||
| | | | | 21,300 | | | | | | | | | | | | 3.450 | | | | | | 5/5/2020 | | | | | | | | | | | | | | | | | | ||||||
| | | | | 30,000 | | | | | | | | | | | | 2.875 | | | | | | 4/4/2023 | | | | | | | | | | | | | | | | | | ||||||
| | | | | 62,700 | | | | | | | | | | | | 4.875 | | | | | | 3/28/2024 | | | | | | | | | | | | | | | | | | ||||||
| | | | | 6,600 | | | | | | | | | | | | 8.070 | | | | | | 4/8/2025 | | | | | | | | | | | | | | | | | | ||||||
| | | | | 73,200 | | | | | | | | | | | | 4.690 | | | | | | 6/7/2026 | | | | | | | | | | | | | | | | | | ||||||
| | | | | 89,250 | | | | | | | | | | | | 5.600 | | | | | | 2/24/2027 | | | | | | | | | | | | | | | | | | ||||||
| | | | | | | | | | | 66,210(1) | | | | | | 7.900 | | | | | | 3/15/2028 | | | | | | | | | | | | | | | | | | ||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 244,314 | | | | | | 1,974,057 | | | | | | ||||||
Kathleen P. Bloch, CPA
|
| | | | 53,200 | | | | | | | | | | | | 4.875 | | | | | | 3/28/2024 | | | | | | | | | | | | | | | | | | ||||||
| | | | | 5,600 | | | | | | | | | | | | 8.070 | | | | | | 4/8/2025 | | | | | | | | | | | | | | | | | | ||||||
| | | | | 75,650 | | | | | | | | | | | | 5.600 | | | | | | 2/24/2027 | | | | | | | | | | | | | | | | | | ||||||
| | | | | | | | | | | 56,100(1) | | | | | | 7.900 | | | | | | 3/15/2028 | | | | | | | | | | | | | | | | | | ||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 215,572 | | | | | | 1,741,822 | | | | | | ||||||
Eric Mortensen, MD
|
| | | | 40,000 | | | | | | | | | | | | 4.500 | | | | | | 5/11/2017 | | | | | | | | | | | | | | | | | | ||||||
| | | | | 38,250 | | | | | | | | | | | | 5.600 | | | | | | 5/11/2017 | | | | | | | | | | | | | | | | | | ||||||
| | | | | | | | | | | 48,000(1) | | | | | | 7.900 | | | | | | 3/15/2028 | | | | | | | | | | | | | | | | | | ||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 129,334 | | | | | | 1,045,019 | | | | | | ||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | |
Option Awards
|
| |
Stock Awards
|
| ||||||||||||||||||
Name
|
| |
Number of
Shares Acquired on Exercise (#) |
| |
Value
Realized on Exercise ($) |
| |
Number
of Shares Acquired on Vesting (#) |
| |
Value
Realized on Vesting ($)(1) |
| ||||||||||||
Phillip P. Chan, MD, PhD
|
| | | | 100,755 | | | | | $ | 787,388 | | | | | | 36,542 | | | | | | 321,333 | | |
Vincent J. Capponi, MS
|
| | | | 192,000 | | | | | $ | 1,470,908 | | | | | | 32,312 | | | | | | 284,149 | | |
Kathleen P. Bloch, CPA
|
| | | | 122,000 | | | | | $ | 618,140 | | | | | | 29,504 | | | | | | 259,453 | | |
Eric R. Mortensen, MD
|
| | | | | | | | | | | | | | | | 4,666 | | | | | | 36,628 | | |
Payment Type
|
| |
Termination
following Change of Control |
| |
Termination
Without Cause or Voluntary Termination for Good Reason |
| |
Termination
for Cause or Expiration of Employment Agreement |
| |
Death or
Disability |
| ||||||||||||
Severance payment
|
| | | $ | 400,000 | | | | | $ | 230,769 | | | | | | — | | | | | | — | | |
Health and Welfare Benefits
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Stock Options
|
| | | | — | | | | | $ | 1,371,465 | | | | | | — | | | | | | — | | |
Restricted Stock Units
|
| | | $ | 2,086,329 | | | | | $ | 2,086,329 | | | | | | — | | | | | | — | | |
Excise Tax and Gross-Ups
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
TOTAL
|
| | | $ | 2,486,329 | | | | | $ | 3,688,563 | | | | | | — | | | | | | — | | |
Payment Type
|
| |
Termination
following Change of Control |
| |
Termination
Without Cause or Voluntary Termination for Good Reason |
| |
Termination
for Cause or Expiration of Employment Agreement |
| |
Death or
Disability |
| ||||||||||||
Severance payment
|
| | | $ | 306,462 | | | | | $ | 306,462 | | | | | | — | | | | | | — | | |
Health and Welfare Benefits
|
| | | $ | 19,189 | | | | | $ | 19,189 | | | | | | — | | | | | | — | | |
Stock Options
|
| | | | — | | | | | $ | 1,012,294 | | | | | | — | | | | | | — | | |
Restricted Stock Units
|
| | | $ | 1,974,057 | | | | | $ | 1,974,057 | | | | | | — | | | | | | — | | |
Excise Tax and Gross-Ups
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
TOTAL
|
| | | $ | 2,299,708 | | | | | $ | 3,312,002 | | | | | | — | | | | | | — | | |
Payment Type
|
| |
Termination
following Change of Control |
| |
Termination
Without Cause or Voluntary Termination for Good Reason |
| |
Termination
for Cause or Expiration of Employment Agreement |
| |
Death or
Disability |
| ||||||||||||
Severance payment
|
| | | $ | 221,250 | | | | | $ | 147,500 | | | | | | — | | | | | | — | | |
Health and Welfare Benefits
|
| | | $ | 12,932 | | | | | $ | 12,932 | | | | | | — | | | | | | — | | |
Stock Options
|
| | | | — | | | | | $ | 368,272 | | | | | | — | | | | | | — | | |
Restricted Stock Units
|
| | | $ | 1,741,822 | | | | | $ | 1,741,822 | | | | | | — | | | | | | — | | |
Excise Tax and Gross-Ups
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
TOTAL
|
| | | $ | 1,976,004 | | | | | $ | 2,270,526 | | | | | | — | | | | | | — | | |
Payment Type
|
| |
Termination
following Change of Control |
| |
Termination
Without Cause or Voluntary Termination for Good Reason |
| |
Termination
for Cause or Expiration of Employment Agreement |
| |
Death or
Disability |
| ||||||||||||
Severance payment
|
| | | $ | 169,500 | | | | | $ | 169,500 | | | | | | — | | | | | | — | | |
Health and Welfare Benefits
|
| | | $ | 12,151 | | | | | $ | 12,151 | | | | | | — | | | | | | — | | |
Stock Options
|
| | | | — | | | | | | 288,775 | | | | | | — | | | | | | — | | |
Restricted Stock Units
|
| | | $ | 1,045,019 | | | | | $ | 1,045,019 | | | | | | — | | | | | | — | | |
Excise Tax and Gross-Ups
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
TOTAL
|
| | | $ | 1,226,670 | | | | | $ | 1,515,445 | | | | | | — | | | | | | — | | |
Plan category
|
| |
Number of
securities to be issued upon exercise of outstanding options, warrants and rights |
| |
Weighted-
average exercise price of outstanding options, warrants and rights |
| |
Number of
securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) |
| |||||||||
| | |
(a)
|
| |
(b)
|
| |
(c)
|
| |||||||||
Equity compensation plans approved by security
holders |
| | | | 2,704,605 | | | | | $ | 6.42 | | | | | | 2,028,011 | | |
Equity compensation plans not approved by security holders
|
| | | | 953,857 | | | | | $ | 4.16 | | | | | | 166,358 | | |
Total
|
| | | | 3,658,462 | | | | | $ | 4.63 | | | | | | 2,194,369 | | |
Name and Position
|
| |
Number of
Options |
| |
Number of
Restricted Stock Units |
| |
Total
|
| |||||||||
Phillip P. Chan, MD, PhD
|
| | | | 250,450 | | | | | | 331,125 | | | | | | 581,575 | | |
Vincent J. Capponi, MS
|
| | | | 235,260 | | | | | | 308,558 | | | | | | 543,818 | | |
Kathleen P. Bloch, MBA, CPA
|
| | | | 199,350 | | | | | | 274,083 | | | | | | 473,433 | | |
Eric R. Mortensen, MD, PhD
|
| | | | 126,250 | | | | | | 138,620 | | | | | | 264,870 | | |
All current executive officers, as a group
|
| | | | 811,310 | | | | | | 1,052,386 | | | | | | 1,863,696 | | |
All current directors who are not executive officers, as a group
|
| | | | 230,975 | | | | | | 277,200 | | | | | | 508,175 | | |
All current employees who are not executive officers, as a group
|
| | | | 2,109,766 | | | | | | 668,414 | | | | | | 2,778,180 | | |
| | |
2018
|
| |
2017
|
| ||||||
Audit Fees(1)
|
| | | $ | 177,500 | | | | | $ | 176,500 | | |
Audit Related Fees(2)
|
| | | | 19,300 | | | | | | 59,116 | | |
Tax Fees(3)
|
| | | | 18,025 | | | | | | 19,840 | | |
All Other Fees(4)
|
| | | | — | | | | | | — | | |
Total
|
| | | $ | 214,825 | | | | | $ | 255,456 | | |
|
| | |
Page
|
| |||
| | | | B-3 | | | |
| | | | B-3 | | | |
| | | | B-3 | | | |
| | | | B-3 | | | |
| | | | B-3 | | | |
| | | | B-3 | | | |
| | | | B-4 | | | |
| | | | B-5 | | | |
| | | | B-5 | | | |
| | | | B-5 | | | |
| | | | B-5 | | | |
| | | | B-5 | | | |
| | | | B-5 | | | |
| | | | B-5 | | | |
| | | | B-6 | | | |
| | | | B-6 | | | |
| | | | B-6 | | | |
| | | | B-6 | | | |
| | | | B-6 | | | |
| | | | B-6 | | | |
| | | | B-6 | | | |
| | | | B-7 | | | |
| | | | B-7 | | | |
| | | | B-8 | | | |
| | | | B-8 | | | |
| | | | B-9 | | | |
| | | | B-10 | | | |
| | | | B-10 | | | |
| | | | B-10 | | | |
| | | | B-12 | | | |
| | | | B-12 | | | |
| | | | B-12 | | | |
| | | | B-12 | | | |
| | | | B-13 | | | |
| | | | B-13 | | | |
| | | | B-13 | | | |
| | | | B-13 | | | |
| | | | B-14 | | | |
| | | | B-14 | | |
| | |
Page
|
| |||
| | | | B-14 | | | |
| | | | B-14 | | | |
| | | | B-15 | | | |
| | | | B-15 | | | |
| | | | B-15 | | | |
| | | | B-15 | | | |
| | | | B-16 | | | |
| | | | B-16 | | | |
| | | | B-16 | | | |
| | | | B-17 | | | |
| | | | B-17 | | | |
| | | | B-17 | | | |
| | | | B-17 | | | |
| | | | B-17 | | | |
| | | | B-17 | | | |
| | | | B-17 | | | |
| | | | B-18 | | | |
| | | | B-18 | | | |
| | | | B-18 | | | |
| | | | B-18 | | |